Home โบ Lung Cancer
Lung Cancer clinical trials recruiting in the U.S.
349 studies for Lung Cancer are recruiting participants at sites across the United States.
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
Cities with the most studies
- Houston, TX78 studies
- Boston, MA63 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Chicago, IL43 studies
- Arlington, VA42 studies
- Washington, DC41 studies
- Baltimore, MD41 studies
- Nashville, TN39 studies
- St. Louis, MO37 studies
- Columbus, OH36 studies
- Philadelphia, PA36 studies
- Seattle, WA34 studies
- Durham, NC33 studies
- Tampa, FL31 studies
- Atlanta, GA28 studies
- San Antonio, TX27 studies
- Portland, OR27 studies
- Dallas, TX26 studies
- San Diego, CA26 studies
- Cleveland, OH26 studies
- Edison, NJ25 studies
- Pittsburgh, PA24 studies
- New Haven, CT24 studies
- Baldwin Park, CA23 studies
- Ann Arbor, MI23 studies
- Orlando, FL23 studies
- San Francisco, CA23 studies
- Sacramento, CA23 studies
- Queens, NY22 studies
- Miami, FL22 studies
- Rochester, MN21 studies
- Milwaukee, WI21 studies
- Mountain View, CA20 studies
- Oklahoma City, OK20 studies
- Minneapolis, MN20 studies
- Salt Lake City, UT19 studies
- Aurora, CO19 studies
- Detroit, MI19 studies
- Evanston, IL19 studies
By state
- Alabama15 studies
- Alaska9 studies
- Arizona34 studies
- Arkansas19 studies
- California114 studies
- Colorado38 studies
- Connecticut32 studies
- Delaware11 studies
- District of Columbia27 studies
- Florida79 studies
- Georgia40 studies
- Hawaii8 studies
- Idaho12 studies
- Illinois65 studies
- Indiana24 studies
- Iowa21 studies
- Kansas20 studies
- Kentucky25 studies
- Louisiana15 studies
- Maine12 studies
- Maryland56 studies
- Massachusetts76 studies
- Michigan45 studies
- Minnesota42 studies
- Mississippi15 studies
- Missouri44 studies
- Montana13 studies
- Nebraska19 studies
- Nevada9 studies
- New Hampshire12 studies
- New Jersey43 studies
- New Mexico15 studies
- New York92 studies
- North Carolina50 studies
- North Dakota15 studies
- Ohio66 studies
- Oklahoma21 studies
- Oregon31 studies
- Pennsylvania57 studies
- Rhode Island6 studies
- South Carolina22 studies
- South Dakota14 studies
- Tennessee58 studies
- Texas101 studies
- Utah22 studies
- Vermont8 studies
- Virginia60 studies
- Washington44 studies
- West Virginia11 studies
- Wisconsin33 studies
Recently updated studies
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RecruitingPhase 3
Ages 18 to 100 ยท All sexes ยท Updated Nov 13, 2026 ยท NCT05920356A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
RecruitingPhase 2/3
Ages 18 and older ยท All sexes ยท Updated Nov 13, 2026 ยท NCT07063745Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Nov 13, 2026 ยท NCT06780098EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
RecruitingHealthy volunteers welcome
Ages 40 to 80 ยท All sexes ยท Updated Nov 13, 2026 ยท NCT06716580Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06909201Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RecruitingPhase 2/3
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT07100080Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RecruitingObservational study
Ages 2 to 100 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT01950572This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06758401Evaluation for NCI Surgery Branch Clinical Research Protocols
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT00001823Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06498635BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT07625644Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT04267848Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Recruiting
Ages 50 to 80 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT07168993Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RecruitingPhase 3
Ages 70 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06096844A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT07458347A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients
Recruiting
Ages 50 to 77 ยท All sexes ยท Updated Nov 10, 2026 ยท NCT07322367Detection of Genetic Markers of Lung Cancer
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT00280202A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT07020221A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT06312137A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT07099898Collection of Blood From Patients With Cancer
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Nov 9, 2026 ยท NCT00034216Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Nov 9, 2026 ยท NCT07664579Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RecruitingObservational study
Ages 50 to 80 ยท All sexes ยท Updated Nov 9, 2026 ยท NCT05784922Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Nov 9, 2026 ยท NCT00451022Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 6, 2026 ยท NCT06881784From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.